Physician profile
Mark Mendel Sklar
NPI 1720083223
$13,855.74
in general payments reported to CMS, 2019-2025
56 companies · $1,610 in 2025
The $1,610 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,177 · 2020: $1,738 · 2021: $1,933 · 2022: $1,984 · 2023: $2,419 · 2024: $1,996 · 2025: $1,610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,009 · Education: $15.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,008.89 |
| Education | $15.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,973.37 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Amneal Pharmaceuticals LLC | $1,562.22 | 2019-2025 | Unithroid |
| Amgen INC. | $1,122.33 | 2019-2025 | Evenity, Prolia, Enbrel |
| Abbvie INC. | $784.23 | 2019-2025 | Synthroid |
| Sanofi-Aventis U.S. LLC | $760.41 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $739.78 | 2019-2025 | Jardiance, Tradjenta |
| Astrazeneca Pharmaceuticals Lp | $729.00 | 2019-2024 | Farxiga, Saphnelo |
| Novartis Pharmaceuticals Corporation | $691.86 | 2020-2024 | |
| Corcept Therapeutics | $584.97 | 2019-2023 | Korlym |
| Novo Nordisk INC | $539.78 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Horizon Therapeutics Plc | $347.06 | 2019-2023 | Tepezza, Krystexxa |
| Ucb, INC. | $314.41 | 2019-2024 | Cimzia |
| Tandem Diabetes Care, INC. | $282.96 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Janssen Biotech, INC. | $267.36 | 2022-2024 | Simponi, Stelara, Remicade |
| Abbott Laboratories | $256.01 | 2019-2025 | Freestyle Libre 3 |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $220.02 | 2019-2024 | Tirosint, Licart |
| Xeris Pharmaceuticals, INC. | $212.70 | 2020-2024 | Recorlev, Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $205.43 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $191.94 | 2020-2025 | Strensiq |
| Antares Pharma, INC. | $188.50 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Merck Sharp & Dohme LLC | $180.44 | 2019-2021 | |
| Glaxosmithkline, LLC. | $163.54 | 2019-2021 | |
| Insulet Corporation | $142.83 | 2019-2025 | Omnipod |
| Pfizer INC. | $111.10 | 2019-2024 | |
| Amarin Pharma, INC. | $101.50 | 2019-2021 | |
| Medtronic, INC. | $100.94 | 2022-2025 | Minimed 780g |
| Acella Pharmaceuticals, LLC | $88.73 | 2023-2025 | NP Thyroid 60 |
| Shire North American Group INC | $73.90 | 2019 | |
| Ascendis Pharma Endocrinology INC | $73.30 | 2023-2025 | Yorvipath |
| Takeda Pharmaceuticals U.S.A., INC. | $65.67 | 2020-2021 | |
| Astellas Pharma US INC | $65.33 | 2023-2024 | Veozah |
| Dexcom, INC. | $56.73 | 2019-2023 | Dexcom G6 Transmitter |
| Radius Health, INC. | $56.30 | 2019-2023 | Tymlos |
| Celgene Corporation | $45.45 | 2019 | |
| Arbor Pharmaceuticals, INC. | $41.03 | 2019-2021 | |
| Ultragenyx Pharmaceutical INC. | $40.46 | 2020-2024 | Crysvita |
| Madrigal Pharmaceuticals | $38.95 | 2025 | Rezdiffra |
| Beta Bionics, INC. | $36.67 | 2024 | Ilet Bionic Pancreas |
| Mannkind Corporation | $35.12 | 2021-2022 | |
| Genentech USA, INC. | $34.90 | 2023-2024 | Actemra |
| Tolmar, INC. | $29.37 | 2025 | Jatenzo |
| Cequr Corporation | $28.40 | 2024 | Cequr Simplicity |
| Neurocrine Biosciences, INC. | $25.30 | 2025 | |
| Medtronic Minimed, INC. | $24.63 | 2019 | |
| Mallinckrodt Enterprises LLC | $22.96 | 2019 | |
| Mallinckrodt Hospital Products INC. | $22.96 | 2020 | |
| Sobi, INC | $22.56 | 2020 | |
| Kyowa Kirin, INC. | $20.11 | 2025 | |
| Sebela Pharmaceuticals INC. | $19.49 | 2019 | |
| Genzyme Corporation | $19.12 | 2020 | |
| Recordati_rare_diseases_inc. | $18.27 | 2023 | Isturisa, Signifor Lar |
| Vivus LLC | $17.54 | 2019 | |
| Aurinia Pharma U.S., INC. | $17.48 | 2022 | |
| Currax Pharmaceuticals LLC | $15.00 | 2025 | Contrave |
| Hikma Pharmaceuticals USA | $13.77 | 2019 | |
| Gilead Sciences, INC. | $11.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Sklar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.